New Risk • Jun 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (AU$19.6m market cap, or US$14.1m). Reported Earnings • Mar 03
First half 2026 earnings released: EPS: AU$0.003 (vs AU$0.002 in 1H 2025) First half 2026 results: EPS: AU$0.003 (up from AU$0.002 in 1H 2025). Revenue: AU$11.9m (down 24% from 1H 2025). Net income: AU$413.2k (up 50% from 1H 2025). Profit margin: 3.5% (up from 1.8% in 1H 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. 공고 • Oct 10
Star Combo Pharma Limited, Annual General Meeting, Nov 25, 2025 Star Combo Pharma Limited, Annual General Meeting, Nov 25, 2025. Declared Dividend • Aug 28
Dividend of AU$0.0037 announced Shareholders will receive a dividend of AU$0.0037. Ex-date: 14th October 2025 Payment date: 31st October 2025 Dividend yield will be 1.9%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (20% earnings payout ratio) and cash flows (4% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has grown by 36% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • Aug 27
Full year 2025 earnings released: EPS: AU$0.029 (vs AU$0.006 in FY 2024) Full year 2025 results: EPS: AU$0.029 (up from AU$0.006 in FY 2024). Revenue: AU$27.8m (up 6.9% from FY 2024). Net income: AU$3.98m (up 433% from FY 2024). Profit margin: 14% (up from 2.9% in FY 2024). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. 공고 • Aug 27
Star Combo Pharma Limited announces Annual dividend, payable on October 31, 2025 Star Combo Pharma Limited announced Annual dividend of AUD 0.0037 per share payable on October 31, 2025, ex-date on October 14, 2025 and record date on October 15, 2025. Board Change • May 06
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Independent Non-Executive Chairman Richard Allely was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 공고 • Apr 16
Star Combo Pharma Limited Announces Insurance Claim Settlement Star Combo Pharma Limited advised that it and its insurer have settled Star Combo's damaged contents and stock claims arising from the two fires at the Star Combo factory premises in 2022. The settlement terms include the payment to Star Combo of $5million. New Risk • Apr 09
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$15.5m (US$9.39m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Market cap is less than US$10m (AU$15.5m market cap, or US$9.39m). New Risk • Nov 11
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$14.9m (US$9.79m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (AU$14.9m market cap, or US$9.79m). Minor Risk Paying a dividend despite having no free cash flows. 공고 • Oct 04
Star Combo Pharma Limited, Annual General Meeting, Nov 26, 2024 Star Combo Pharma Limited, Annual General Meeting, Nov 26, 2024. 공고 • Aug 23
Star Combo Pharma Limited Announces Dividend for the Year Ended June 30, 2024, Payable on October 31, 2024 Star Combo Pharma Limited announced ordinary dividend of AUD 0.00370000 for the year ended June 30, 2024. Record Date is October 15, 2024; Ex- Date is October 14, 2024; Payment date is October 31, 2024. Reported Earnings • Aug 22
Full year 2024 earnings released: EPS: AU$0.01 (vs AU$0.03 loss in FY 2023) Full year 2024 results: EPS: AU$0.01 (up from AU$0.03 loss in FY 2023). Revenue: AU$26.5m (up 7.0% from FY 2023). Net income: AU$747.3k (up AU$4.75m from FY 2023). Profit margin: 2.8% (up from net loss in FY 2023). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. New Risk • Jun 05
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$14.9m (US$9.87m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Market cap is less than US$10m (AU$14.9m market cap, or US$9.87m). Board Change • May 03
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Non-Executive Chairman Richard Allely was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Feb 19
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Non-Executive Chairman Richard Allely was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Jan 25
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Non-Executive Chairman Richard Allely was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Dec 29
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Non-Executive Chairman Richard Allely was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Dec 04
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Non-Executive Chairman Richard Allely was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 공고 • Oct 17
Star Combo Pharma Limited, Annual General Meeting, Nov 28, 2023 Star Combo Pharma Limited, Annual General Meeting, Nov 28, 2023. Reported Earnings • Aug 30
Full year 2023 earnings released: AU$0.03 loss per share (vs AU$0.005 loss in FY 2022) Full year 2023 results: AU$0.03 loss per share (further deteriorated from AU$0.005 loss in FY 2022). Revenue: AU$25.0m (up 8.8% from FY 2022). Net loss: AU$4.00m (loss widened 475% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings. New Risk • Aug 29
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 26% per year over the past 5 years. Market cap is less than US$10m (AU$14.9m market cap, or US$9.55m). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Board Change • Aug 25
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Non-Executive Chairman Richard Allely was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Aug 09
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Non-Executive Chairman Richard Allely was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • May 01
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Non-Executive Chairman Richard Allely was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Feb 15
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Chairman Richard Allely was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Jan 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Chairman Richard Allely was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Dec 19
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Chairman Richard Allely was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Chairman Richard Allely was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공고 • Oct 07
Star Combo Pharma Limited, Annual General Meeting, Nov 29, 2022 Star Combo Pharma Limited, Annual General Meeting, Nov 29, 2022. 공고 • Aug 30
Star Combo Pharma Limited Announces Resignation of Ziye Sui as Non- Executive Director Star Combo Pharma Limited announced that it has received the resignation as a Non- Executive Director from Dr. Ziye Sui due to her full time commitments elsewhere. The resignation is effective 24 August 2022. The Company has accepted the resignation with regret. Reported Earnings • Aug 24
Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.058 loss in FY 2021) Full year 2022 results: AU$0.005 loss per share (up from AU$0.058 loss in FY 2021). Revenue: AU$23.9m (down 11% from FY 2021). Net loss: AU$696.3k (loss narrowed 91% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings. Board Change • Aug 19
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Chairman Richard Allely was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Chairman Richard Allely was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 06
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Chairman Richard Allely was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 26
First half 2022 earnings: Revenues and EPS in line with analyst expectations First half 2022 results: EPS: AU$0 (down from AU$0.004 in 1H 2021). Revenue: AU$11.8m (down 20% from 1H 2021). Net loss: AU$997 (down 100% from profit in 1H 2021). Profit margin: 0% (down from 3.6% in 1H 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 28% per year whereas the company’s share price has fallen by 30% per year. Board Change • Feb 01
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Chairman Richard Allely was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Jan 14
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Chairman Richard Allely was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Dec 01
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Chairman Richard Allely was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 21
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Chairman Richard Allely was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 26
Full year 2021 earnings released: AU$0.058 loss per share (vs AU$0.004 loss in FY 2020) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: AU$28.1m (down 28% from FY 2020). Net loss: AU$7.88m (loss widened AU$7.53m from FY 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 24
First half 2021 earnings released: EPS AU$0.004 (vs AU$0.01 loss in 1H 2020) The company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: AU$14.7m (down 31% from 1H 2020). Net income: AU$530.4k (up AU$1.76m from 1H 2020). Profit margin: 3.6% (up from net loss in 1H 2020). Is New 90 Day High Low • Feb 12
New 90-day low: AU$0.27 The company is down 22% from its price of AU$0.34 on 13 November 2020. The Australian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 3.0% over the same period. Is New 90 Day High Low • Jan 11
New 90-day low: AU$0.29 The company is down 16% from its price of AU$0.35 on 13 October 2020. The Australian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 4.0% over the same period.